Parkinson's disease

Editors at the journal Nature Medicine recently asked researchers and public health experts from around the world to identify clinical trials that will shape medicine in 2023.  They came up with a varied list of candidates, from cervical and prostate cancer screening protocols to gene therapy for muscular dystrophy and new drugs for Parkinson’s disease and Alzheimer’s disease.  The selections are arbitrary and idiosyncratic, but they are interesting, nevertheless. 
Parkinson’s Disease is one of several degenerative diseases in our neurologic system. It has a celebrity patient, Michael J. Fox. Still, with a million patients living with the disease in the US and sixty thousand new diagnoses annually, it lacks a biomarker to aid in early detection. An artificial intelligence program looking at nocturnal breathing may change that and, ultimately, how we care for these patients.
The actor and musician knows how to convey a message that effects medical change, helped in part by his visit top be with sick kids at Children's Hospital Los Angeles. Now, let's see if Hollywood follows suit. 
In 1976, Barry Kidston, a chemistry grad student, would find out the hard way that you had better be careful with your reaction conditions when making psychoactive drugs. He got a little sloppy, and instead of making a pure derivative of Demerol, got an impurity in the batch, which gave him Parkinson's with one injection. Six years later, a group of six "frozen addicts" suffered the same fate. Crazy brain chemistry.
The prevalence of dementia in the United States significantly declined from 11.6 percent in 2000 to 8.8 percent in 2012. The consequence of this impacts retirement, families, the health care system, life expectancy, morbidity and mortality, pensions, housing, transportation and countless societal realms. 
Parkinson s Disease (PD), a neurodegenerative disorder of the central nervous system, currently affects one million people in the United States, and an estimated 50,000 60,000 new cases of PD are diagnosed each year.
A small pilot study of gene therapy for Parkinson s disease showed improvement in severe motor symptoms. There were no side effects of significance, and all three doses had beneficial effect.